Art

J-GLOBAL ID：202102280800142005   Reference number：21A0631345

ESMO meeting 2020 Lung cancer.

ESMO meeting report 1)肺がん

Author (1)： GOTO YASUSHI (国立がん研究セ 中央病院 呼吸器内科)
Material： 月刊腫瘍内科  (腫瘍内科)
Volume： 27  Issue： 2  Page： 198-203  Publication year： Feb. 28, 2021 
JST Material Number： L6395A  ISSN： 1881-6568  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： ESMO ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A0631345&from=J-GLOBAL&jstjournalNo=L6395A") }}

JST classification (2)： Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Clinical oncology in general  (GE03010Y)

Substance index (3)： Osimertinib mesilate ,  Paclitaxel ,  Lorlatinib

Reference (16)：

• Tsuboi M, Wu YL, He J, et al. Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence. Ann Oncol 2020 ; 31 : S1177.
• Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New Engl J Med 2020 ; 383: 1711.
• Zhong W-Z, Wang Q, Mao W-M, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC : Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol 2020 : JCO2001820.
• Toi Y, Hayashi H, Fujimoto D, et al. A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L). Ann Oncol 2020 ; 31 : S813.
• Shaw AT, Bauer TM, Marinis F de, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 2020 ; 383 : 2018.

Terms in the title (2)： ESMO ,  肺がん